Use of insulin immunoassays in clinical studies involving rapid-acting insulin analogues: Bi-insulin IRMA preliminary assessment
Authors:
- Arnaud AginAAArnaud Agin
- Nathalie JeandidierNJNathalie Jeandidier
- Françoise GasserFGFrançoise Gasser
- Daniel GruckerDGDaniel Grucker
- Rémy SapinRSRémy Sapin
- 1 January 2006
- journal article
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 44 (11) , 1379-82
Abstract
Clin Chem Lab Med 2006;44:1379–82.Keywords
This publication has 8 references indexed in Scilit:
- Performance Evaluation and Cross-Reactivity from Insulin Analogs with the ARCHITECT Insulin Assay,Clinical Chemistry, 2006
- Dose Response of Inhaled Dry-Powder Insulin and Dose Equivalence to Subcutaneous Insulin LisproDiabetes Care, 2005
- Cross-Reactivity of Three Recombinant Insulin Analogs with Five Commercial Insulin ImmunoassaysClinical Chemistry, 2004
- Use of a Novel Double-Antibody Technique to Describe the Pharmacokinetics of Rapid-Acting Insulin AnalogsDiabetes Care, 2002
- Immune Responses to Insulin Aspart and Biphasic Insulin Aspart in People With Type 1 and Type 2 DiabetesDiabetes Care, 2002
- A New Insulin Immunoassay Specific for the Rapid-Acting Insulin Analog, Insulin Aspart, Suitable for Bioavailability, Bioequivalence, and Pharmacokinetic StudiesClinical Biochemistry, 2000
- Assays for Insulin, Proinsulin(S) and C-PeptideAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 1999
- Immunologic Effects of Insulin Lispro [Lys (B28), Pro (B29) Human Insulin] in IDDM and NIDDM Patients Previously Treated With InsulinDiabetes, 1996